Published in Osteoporos Int on October 27, 2009
Teriparatide, a nonsurgical solution for femoral nonunion? A report of three cases. Osteoporos Int (2012) 1.29
Atrophic femoral nonunion successfully treated with teriparatide. Eur J Orthop Surg Traumatol (2012) 1.23
Current medical treatment strategies concerning fracture healing. Clin Cases Miner Bone Metab (2013) 0.95
Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J Bone Joint Surg Am (2013) 0.93
Successful treatment of nonunion with teriparatide after failed ankle arthrodesis for Charcot arthropathy. Osteoporos Int (2013) 0.90
Teriparatide - Indications beyond osteoporosis. Indian J Endocrinol Metab (2012) 0.89
Effective treatment of a steroid-induced femoral neck fracture nonunion with a once-weekly administration of teriparatide in a rheumatoid patient: a case report. Arch Osteoporos (2013) 0.88
Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial. Clin Orthop Relat Res (2016) 0.88
Teriparatide Therapy as an Adjuvant for Tissue Engineering and Integration of Biomaterials. J Mater Res (2011) 0.84
Biologic adjuvants for fracture healing. Arthritis Res Ther (2012) 0.82
Effective treatment of delayed union of a lumbar vertebral fracture with daily administration of teriparatide in a patient with diffuse idiopathic skeletal hyperostosis. Eur Spine J (2015) 0.81
Use of Teriparatide to improve fracture healing: What is the evidence? World J Orthop (2015) 0.79
The Effect of Teriparatide on Fracture Healing of Osteoporotic Patients: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int (2016) 0.78
Teriparatide in Fracture Non-Unions. Transl Med UniSa (2014) 0.76
The role of peptides in bone healing and regeneration: a systematic review. BMC Med (2016) 0.75
Teriparatide as a nonoperative treatment for tibial and femoral fracture nonunion: A case report. Medicine (Baltimore) (2017) 0.75
Radiographic features of teriparatide-induced healing of femoral fractures. Bone Rep (2015) 0.75
Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: A retrospective comparative study. BMC Musculoskelet Disord (2017) 0.75
[Use of osteoanabolics in fracture nonunion]. Orthopade (2015) 0.75
Bone-grafting and bone-graft substitutes. J Bone Joint Surg Am (2002) 3.64
Current and future clinical applications of bone morphogenetic proteins in orthopaedic trauma surgery. Int Orthop (2007) 1.83
The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology (1997) 1.81
Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J Bone Joint Surg Am (2008) 1.40
Operative fixation of chest wall fractures: an underused procedure? Am Surg (2007) 1.23
New technologies for the enhancement of skeletal repair. Injury (2007) 1.17
Parathyroid hormone--a drug for orthopedic surgery? Acta Orthop Scand (2004) 1.16
Metabolic and endocrine abnormalities in patients with nonunions. J Orthop Trauma (2007) 1.13
Available biological treatments for complex non-unions. Injury (2007) 1.06
An economic analysis of management strategies for closed and open grade I tibial shaft fractures. Acta Orthop (2005) 1.05
Sternal nonunion: a review of current treatments and a new method of rigid fixation. Ann Plast Surg (2005) 1.01
Sternal fracture--a modern review. Arch Emerg Med (1993) 0.97
79-year-old post-menopausal woman with humerus fracture during teriparatide treatment. Aging Clin Exp Res (2007) 0.92
Teriparatide and fracture healing in cortical bone. Endocr Pract (2004) 0.90
Surgical approach to fragility fractures: problems and perspectives. Aging Clin Exp Res (2007) 0.85
Clinical follow-up and immunogenetic studies of 32 patients with eosinophilia-myalgia syndrome. Lancet (1991) 2.31
Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest (1997) 1.89
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum (2001) 1.58
Cutaneous manifestations of the L-tryptophan-associated eosinophilia-myalgia syndrome: a spectrum of sclerodermatous skin disease. J Am Acad Dermatol (1990) 1.52
Fibrogenic growth factors in the eosinophilia-myalgia syndrome and the toxic oil syndrome. Arch Dermatol (1994) 1.40
The differentiation and function of myofibroblasts is regulated by mast cell mediators. J Invest Dermatol (2001) 1.33
Elevated levels of 92-kd type IV collagenase (matrix metalloproteinase 9) in giant cell arteritis. Arthritis Rheum (1996) 1.02
Preliminary observations on the role of magnetic resonance imaging for polymyositis and dermatomyositis. Ann Rheum Dis (1987) 0.94
Electroconvulsive therapy and cyclophosphamide in combination for severe neuropsychiatric lupus with catatonia. Am J Med (1990) 0.94
Mast cell changes in scleroderma. Presence of MCT cells in the skin and evidence of mast cell activation. Arthritis Rheum (1992) 0.93
Murine mast cells express two types of C1q receptors that are involved in the induction of chemotaxis and chemokinesis. J Immunol (1995) 0.92
Mast cells are potent regulators of endothelial cell adhesion molecule ICAM-1 and VCAM-1 expression. J Cell Physiol (1995) 0.86
Superior oblique tenosynovitis (Brown's syndrome) as a manifestation of adult Still's disease. J Rheumatol (1987) 0.86
Cutaneous polyarteritis nodosa. N Y State J Med (1988) 0.86
Simultaneous onset of systemic sclerosis (scleroderma) and lung cancer: a case report and histologic analysis of fibrogenic peptides. Am J Med (1992) 0.86
L-tryptophan-associated eosinophilic perimyositis, neuritis, and fasciitis. A clinicopathologic and laboratory study of 25 patients. Medicine (Baltimore) (1990) 0.82
Mast cells induce T-cell adhesion to human fibroblasts by regulating intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression. J Invest Dermatol (1995) 0.80
Effects of commonly prescribed nonsteroidal anti-inflammatory drugs on thyroid hormone measurements. Am J Med (1994) 0.79
Anti-laminin autoantibodies in collagen vascular diseases: the use of adequate controls in studies of autoimmune responses to laminin. Ann Rheum Dis (1994) 0.79
Eosinophilic neuritis, perimyositis, and vasculitis associated with ingestion of L-tryptophan. J Rheumatol (1990) 0.76
An IgE response to spirochete antigen in patients with Lyme disease. Zentralbl Bakteriol Mikrobiol Hyg A (1986) 0.76
Late cutaneous Lyme disease: acrodermatitis chronica atrophicans. Am J Med (1989) 0.76
Mast cell tryptase does not alter matrix metalloproteinase expression in human dermal fibroblasts: further evidence that proteolytically-active tryptase is a potent fibrogenic factor. J Cell Physiol (1999) 0.76
Anti-IgE autoantibodies in systemic sclerosis (scleroderma). Ann Rheum Dis (1989) 0.75
Interleukin-4 levels in the eosinophilia-myalgia syndrome. Am J Med (1991) 0.75
Growth factors in subglottic stenosis. Ann Otol Rhinol Laryngol (1996) 0.75
The coexistence of systemic sclerosis (scleroderma) and Reiter's syndrome. J Rheumatol (1987) 0.75
Sarcoidosis presenting as necrotizing sinus destruction mimicking Wegener's granulomatosis. J Rheumatol (2000) 0.75
Septic arthritis involving the manubriosternal joint. J Rheumatol (1985) 0.75